New drug could slow lung decline in transplant patients
NCT ID NCT03283007
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether nintedanib, a drug already used for lung scarring, can slow the decline in lung function in lung transplant recipients who develop bronchiolitis obliterans syndrome (BOS), a form of chronic rejection. 58 participants received either nintedanib or a placebo twice daily for 6 months. The study measures changes in breathing tests, exercise ability, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nintedanib
What this could lead to
If it works, this could provide a treatment to slow lung function decline and improve survival in lung transplant patients with chronic rejection.
What could go wrong
This is a small, early-phase trial with only 58 participants. The drug may not slow lung decline or could cause side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Foch Hospital
Suresnes, 92150, France